Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Salarius Pharmaceuticals (NASDAQ: SLRX), a clinical-stage biopharmaceutical company, has announced a 1-for-15 reverse stock split effective August 15, 2025. The split aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
Following the split, SLRX's outstanding shares will reduce from approximately 7.6 million to 509,000 shares. Trading on a split-adjusted basis will begin August 18, 2025, under a new CUSIP number 79400X503. The split will uniformly affect all stockholders, with cash provided for fractional shares based on the August 15 closing price.
The reverse split was approved by stockholders on July 8, 2025, and will adjust all outstanding options, warrants, and shares reserved under the 2015 Employee Stock Purchase Plan accordingly.
Salarius Pharmaceuticals (NASDAQ: SLRX), societ脿 biofarmaceutica in fase clinica, ha annunciato un raggruppamento azionario inverso 1 per 15 con efficacia dal 15 agosto 2025. L'operazione ha l'obiettivo di ripristinare la conformit脿 al requisito minimo del Nasdaq di un prezzo di offerta di $1,00.
Al completamento del raggruppamento, le azioni in circolazione passeranno da circa 7,6 milioni a 509.000 azioni. Le negoziazioni rettificate in base al raggruppamento avranno inizio il 18 agosto 2025, con il nuovo CUSIP 79400X503. L'operazione interesser脿 tutti gli azionisti in modo proporzionale; le frazioni di azioni saranno liquidate in contanti calcolati sul prezzo di chiusura del 15 agosto.
Il raggruppamento 猫 stato approvato dagli azionisti l'8 luglio 2025 e adeguer脿 di conseguenza tutte le opzioni, i warrant e le azioni riservate ai sensi del 2015 Employee Stock Purchase Plan.
Salarius Pharmaceuticals (NASDAQ: SLRX), una compa帽铆a biofarmac茅utica en fase cl铆nica, ha anunciado una consolidaci贸n inversa de acciones 1 por 15 con vigencia a partir del 15 de agosto de 2025. La operaci贸n busca recuperar el cumplimiento del requisito m铆nimo de Nasdaq de un precio de oferta de $1.00.
Tras la consolidaci贸n, las acciones en circulaci贸n se reducir谩n de aproximadamente 7,6 millones a 509.000 acciones. La cotizaci贸n ajustada por la consolidaci贸n comenzar谩 el 18 de agosto de 2025, con el nuevo CUSIP 79400X503. La operaci贸n afectar谩 por igual a todos los accionistas; las fracciones de acciones se pagar谩n en efectivo con base en el precio de cierre del 15 de agosto.
La consolidaci贸n fue aprobada por los accionistas el 8 de julio de 2025 y ajustar谩 en consecuencia todas las opciones en circulaci贸n, los warrants y las acciones reservadas bajo el Employee Stock Purchase Plan de 2015.
Salarius Pharmaceuticals (NASDAQ: SLRX), 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎届偓,電� 1雽�15 鞐硲頃�(Reverse Stock Split)鞚� 2025雲� 8鞗� 15鞚茧秬搿� 鞁滍枆頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 臁办箻電� 雮橃姢雼レ潣 斓滌唽 毵れ垬 順戈皜 $1.00 鞖旉贝鞚� 須岆车頃橁赴 鞙勴暅 瓴冹瀰雼堧嫟.
鞐硲頃� 鞁滍枆 頉� 氚滍枆 欤检嫕 靾橂姅 鞎� 760毵� 欤检棎靹� 509,000欤茧 欷勳柎霌媹雼�. 氤戫暕 臁办爼霅� 瓯半灅電� 2025雲� 8鞗� 18鞚茧秬韯� 鞁滌瀾霅橂┌ 靸堧鞖� CUSIP 氩堩樃電� 79400X503鞛呺媹雼�. 鞐硲頃╈潃 氇摖 欤检＜鞐愱矊 霃欖澕頃橁矊 鞝侅毄霅橂┌, 靻岇垬欤检棎 雽�頃挫劀電� 8鞗� 15鞚� 膦呹皜毳� 旮办鞙茧 順勱笀鞙茧 歆�旮夒惄雼堧嫟.
鞚� 鞐硲頃╈潃 2025雲� 7鞗� 8鞚� 欤检＜霌れ潣 鞀轨澑鞚� 氚涭晿鞙茧┌, 鞚挫棎 霐半澕 氇摖 氙胳儊頇� 鞓奠厴, 鞗岆煱韸� 氚� 2015雲� 歆侅洂 欤检嫕甑Г瓿勴殟(ESPP) 頃橃棎 鞓堨暯霅� 欤检嫕鞚� 臁办爼霅╇媹雼�.
Salarius Pharmaceuticals (NASDAQ: SLRX), une soci茅t茅 biopharmaceutique en phase clinique, a annonc茅 un regroupement d'actions inverse de 1 pour 15 prenant effet le 15 ao没t 2025. Cette op茅ration vise 脿 retrouver la conformit茅 avec l'exigence minimale du Nasdaq d'un prix d'offre de 1,00 $.
Apr猫s le regroupement, le nombre d'actions en circulation passera d'environ 7,6 millions 脿 509 000 actions. Les transactions ajust茅es en fonction du regroupement d茅buteront le 18 ao没t 2025 sous le nouveau CUSIP 79400X503. Le regroupement s'appliquera uniform茅ment 脿 tous les actionnaires ; les fractions d'actions seront r茅gl茅es en esp猫ces sur la base du cours de cl么ture du 15 ao没t.
Le regroupement a 茅t茅 approuv茅 par les actionnaires le 8 juillet 2025 et ajustera en cons茅quence toutes les options et warrants en circulation ainsi que les actions r茅serv茅es dans le cadre du Employee Stock Purchase Plan de 2015.
Salarius Pharmaceuticals (NASDAQ: SLRX), ein Biopharmaunternehmen in klinischer Phase, hat eine R眉ckw盲rts-Aktienzusammenlegung im Verh盲ltnis 1 zu 15 angek眉ndigt, die am 15. August 2025 wirksam wird. Der Schritt soll die Einhaltung der Mindestgebotspreisanforderung von Nasdaq in H枚he von $1,00 wiederherstellen.
Nach der Zusammenlegung verringert sich die Zahl der ausstehenden Aktien von etwa 7,6 Millionen auf 509.000 Aktien. Der handel auf zusammenlegungsbereinigter Basis beginnt am 18. August 2025 unter der neuen CUSIP-Nummer 79400X503. Die Zusammenlegung betrifft alle Aktion盲re gleicherma脽en; Bruchst眉cke werden auf Basis des Schlusskurses vom 15. August in bar ausgezahlt.
Die R眉ckw盲rtszusammenlegung wurde am 8. Juli 2025 von den Aktion盲ren genehmigt und wird entsprechend alle noch ausstehenden Optionen, Warrants sowie die f眉r den Employee Stock Purchase Plan von 2015 reservierten Aktien anpassen.
- Potential to regain Nasdaq compliance and maintain listing status
- Stockholder approval already secured for the reverse split
- Significant share consolidation indicates previous stock price weakness
- Risk of failing to maintain minimum bid price even after split
Insights
Salarius' 1-for-15 reverse split aims to maintain Nasdaq listing by boosting share price, but signals concerning financial position.
Salarius Pharmaceuticals has announced a 1-for-15 reverse stock split effective August 15, 2025, reducing its outstanding shares from approximately 7.6 million to 509,000. This drastic consolidation represents a clear defensive move to regain compliance with Nasdaq's $1 minimum bid price requirement - a threshold the company has evidently fallen below.
The reverse split is a technical adjustment that doesn't change Salarius' underlying market capitalization or individual shareholder percentage ownership (except for fractional shares). However, it reveals deeper concerns about the company's financial trajectory. Reverse splits are typically last-resort measures employed by companies experiencing prolonged share price deterioration, often due to fundamental business challenges.
For clinical-stage biotech companies like Salarius, maintaining Nasdaq listing is crucial for accessing capital markets necessary to fund ongoing research and development efforts. The relatively steep 1-for-15 ratio (when shareholders had approved a range from 1-for-4 to 1-for-40) suggests significant downward pressure on share price.
This restructuring also has practical implications - all outstanding options and warrants will undergo proportional adjustments, potentially affecting their economic value. While the reverse split may temporarily boost share price and preserve Nasdaq listing, it doesn't address any underlying business challenges. Without fundamental improvements in clinical progress or financial outlook, the company risks returning to sub-$1 territory, potentially leading to a cycle of additional reverse splits or eventual delisting.
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025. Beginning with the opening of trading on August 18, 2025, Salarius鈥� common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X503.
The reverse stock split is intended to enable Salarius to regain compliance with the
At a special meeting of stockholders held on July 8, 2025, Salarius鈥� stockholders approved the proposal to authorize Salarius鈥� Board of Directors to file an amendment to Salarius鈥� amended and restated certificate of incorporation (鈥淐ertificate of Incorporation鈥�) to effect the reverse split at a ratio to be determined by the Board, ranging from 1-for-4 to 1-for-40. The specific 1-for-15 ratio was subsequently approved by Salarius鈥� Board of Directors and the reverse stock split will be effected by filing a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware.
The reverse split will affect all issued and outstanding shares of Salarius鈥� common stock. At the effective time of the reverse stock split the number of shares of common stock issued and outstanding will be reduced from approximately 7.6 million shares to approximately 509,000 shares. All outstanding options and warrants entitling their holders to purchase shares of Salarius鈥� common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares reserved for future issuance pursuant to Salarius鈥� 2015 Employee Stock Purchase Plan will also be appropriately adjusted. The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of Salarius鈥� shares (except to the extent that the reverse stock split would result in some of the stockholders receiving cash in lieu of fractional shares). Stockholders will receive cash in lieu of fractional shares based on the closing price per share of Salarius鈥� common stock as quoted on the Nasdaq Capital Market on August 15, 2025. The reverse stock split will not reduce the number of authorized shares of common stock or preferred stock or change the par values of Salarius鈥� common stock (which will remain at
Equiniti Trust Company, LLC, (鈥淓quiniti鈥�) is acting as the exchange agent and transfer agent for the reverse stock split. Equiniti will provide instructions to stockholders with physical certificates regarding the process for exchanging their pre-split stock certificates for post-split shares in book-entry form and receiving payment for any fractional shares.
Additional information about the reverse stock split can be found in the Company鈥檚 Definitive Proxy Statement filed with the Securities and Exchange Commission (鈥淪EC鈥�) on May 27, 2025. The Proxy Statement is available at www.sec.gov or at Salarius鈥� website at salariuspharma.com.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals聽is a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius鈥� product portfolio includes seclidemstat, the company鈥檚 lead candidate, which is being studied in an investigator-initiated Phase 1/2 clinical study in hematologic cancers underway at MD Anderson Cancer Center as a potential treatment for MDS and CMML in patients with limited treatment options. SP-3164, the company鈥檚 IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from the National Pediatric Cancer Foundation and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit聽.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as 鈥渕ay,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渆xpect,鈥� 鈥減lan,鈥� 鈥渁nticipate,鈥� 鈥渃ould,鈥� 鈥渋ntend,鈥� 鈥渢arget,鈥� 鈥減roject,鈥� 鈥渆stimate,鈥� 鈥渂elieve,鈥� 鈥減redict,鈥� 鈥減otential鈥� or 鈥渃ontinue鈥� or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the reverse split and the timing thereof and expectations related thereto; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company鈥檚 actual results to differ materially from the results described in or implied by the forward-looking statements. Some factors that may cause the Company鈥檚 actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 鈥淩isk Factors鈥� in the Company鈥檚 most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 鈥淪EC鈥�), in the Company鈥檚 other filings with the SEC, and in the Company鈥檚 future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT:
Alliance Advisors IR
Jody Cain
310-691-7100
FAQ
What is the ratio of Salarius Pharmaceuticals (SLRX) reverse stock split?
Why is SLRX doing a reverse stock split?
How many shares will SLRX have after the reverse split?
When will SLRX start trading on a split-adjusted basis?
What happens to fractional shares in the SLRX reverse split?
